Outlook Therapeutics resubmits BLA for ONS-5010 to FDA

Outlook Therapeutics, Inc.

Resubmitted Biologics License Application for ONS-5010 to FDA on February 28, 2025.
No details on resubmission content, prior FDA actions, or expected review timeline provided.
Resubmission marks a key regulatory step for the company's sole pipeline candidate.

item 8.01

Outlook Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-018717

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.